Advances in personalized cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Three main T cell-based cancer immunotherapies exist: active vaccination, adoptive cell transfer, and immune checkpoint blockade.
• Immune checkpoint blockade has recently shown significant clinical benefits, increasing interest in cancer immunotherapy.
• Understanding the Cancer-Immunity Cycle is vital for advancing cancer immunotherapy.

Purpose of the Study:

• To highlight the importance of personalized cancer immunotherapy.
• To explain how tumors evade anti-tumor immunity through immunoediting and other mechanisms.
• To emphasize the role of neoantigens and genomic information in future personalized immunotherapies.

Main Methods:

• Review of current T cell-based cancer immunotherapy approaches.
• Discussion of tumor immune evasion strategies and the Cancer-Immunity Cycle.
• Exploration of next-generation sequencing for identifying neoantigens.

Main Results:

• Tumors utilize diverse strategies, including immunoediting, to escape anti-tumor immunity.
• Patient-specific immune inhibition necessitates personalized immunotherapy strategies.
• Next-generation sequencing enables identification of patient-specific neoantigens.

Conclusions:

• Personalized cancer immunotherapy must identify patient-specific rate-limiting steps and targets.
• Combining strategies to overcome immune hurdles is crucial for effective treatment.
• Future immunotherapies will integrate patient-specific immunosuppressive mechanisms and neoantigen identification.